In this episode, Sabrina Matucci-Johnson, CEO of Daré Bioscience (Ticker: DARE), shares insights on advancing women’s health products in the biotech industry. She discusses the challenges and strategies for successful commercialization, including leveraging partnerships with pharmaceutical companies, utilizing non-dilutive funding like grants, and the unique approach of using a reverse merger for funding. Sabrina highlights the significance of addressing unmet needs, obtaining FDA approval, and ensuring patient access to innovative products. The episode delves into the importance of clear communication with investors and stakeholders in the fast-paced biotech landscape.

Sabrina’s journey in the biotech industry has been diverse, encompassing roles ranging from research scientist to the Chief Financial Officer of a publicly traded company. This multifaceted experience has given her a comprehensive understanding of the industry’s intricacies and the necessary steps to successfully commercialize products. Her transition to founding Daré Bioscience in 2015 reflects her observation of the unmet needs in women’s health and her determination to address these gaps through innovation and strategic partnerships.

A notable aspect of the conversation is the emphasis on the unique challenges and opportunities within the field of women’s health. Sabrina discusses the lack of pharmaceutical innovation in indications that disproportionately or differentially affect women, underscoring the critical need for focused development in this area. This highlights the potential for significant impact and commercial success in addressing these unmet needs, which has become a central focus for Daré Bioscience.
The conversation delves into the complexities of product development and FDA approval in the biotech industry, shedding light on the daunting statistics of only 8% of new chemical entities gaining FDA approval. Sabrina’s strategic approach to mitigating risk by leveraging known active pharmaceutical ingredients and efficiently running clinical trials underscores the importance of a thoughtful approach to product development.

The discussion on funding strategies, including the decision to pursue a reverse merger to access public markets, offers insights into the financial considerations and strategic planning that underpin the growth and sustainability of a biotech company. Sabrina’s emphasis on the importance of grant funding and tax rebates in supporting early-stage programs and reducing financial risk provides a nuanced perspective on financing options in the biotech landscape.
Sabrina’s insights into the role of communication and education in the biotech industry are particularly noteworthy. Her focus on destigmatizing women’s health issues and ensuring access to credible information reflects a commitment to patient-centric care and public health awareness.

(00:00:46) – Sabrina Matucci-Johnson: A journey through biotechnology
(00:03:47) – Innovation in Women’s Health: Daré’s Strategy
(00:08:51) – The importance of an effective partner strategy for new products
(00:12:31) – Biotech Industry Value Creation Strategies
(00:14:55) – Women’s health: risk minimization in drug development
(00:18:19) – Choosing the right products for development
(00:20:54) – The importance of FDA approval for pharmaceutical companies
(00:23:45) – The decision to go public: Why going public was the appropriate step
(00:26:50) – Funding in the field of women’s medicine
(00:30:09) – Research and development tax credits in Australia
(00:32:22) – The importance of collaboration with external partners and investors
(00:35:42) – Healthcare communications and investments
(00:38:57) – Removing the stigma around women’s issues

All in Her Head: The Truth and Lies Early Medicine Taught Us About Women’s Bodies and Why It Matters Today by Elizabeth Comen

The Stand by Stephen King



Comments are closed